首页 / 院系成果 / 成果详情页

Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats  期刊论文  

  • 编号:
    467e775e-0462-415f-9f7b-90da2eb360df
  • 作者:
    Liu, Na[1];Xu, Liuqing[1];Shi, Yingfeng[1];Fang, Lu[1];Gu, Hongwei[1];Wang, Hongrui[1];Ding, Xiaoqiang(丁小强)*[2]Zhuang, Shougang[1,3,4];
  • 语种:
    英文
  • 期刊:
    ONCOTARGET ISSN:1949-2553 2017 年 8 卷 20 期 (33807 - 33826) ; MAY 16
  • 收录:
  • 关键词:
  • 摘要:

    The pathogenesis of hyperuricemia-induced chronic kidney disease is largely unknown. In this study, we investigated whether extracellular signal-regulated kinases1/2 (ERK1/2) would contribute to the development of hyperuricemic nephropathy (HN). In a rat model of HN induced by feeding mixture of adenine and potassium oxonate, increased ERK1/2 phosphorylation and severe glomerular sclerosis and renal interstitial fibrosis were evident, in parallel with diminished levels of renal function and increased urine microalbumin excretion. Administration of U0126, which is a selective inhibitor of the ERK1/2 pathway, improved renal function, decreased urine microalbumin and inhibited activation of renal interstitial fibroblasts as well as accumulation of extracellular proteins. U0126 also inhibited hyperuricemia-induced expression of multiple profibrogenic cytokines/chemokines and infiltration of macrophages in the kidney. Furthermore, U0126 treatment suppressed xanthine oxidase, which mediates uric acid production. It also reduced expression of the urate anion exchanger 1, which promotes reabsorption of uric acid, and preserved expression of organic anion transporters 1 and 3, which accelerate uric acid excretion in the kidney of hyperuricemic rats. Finally, U0126 inhibited phosphorylation of Smad3, a key mediator in transforming growth factor (TGF-beta) signaling. In cultured renal interstitial fibroblasts, inhibition of ERK1/2 activation by siRNA suppressed uric acid-induced activation of renal interstitial fibroblasts. Collectively, pharmacologic targeting of ERK1/2 can alleviate HN by suppressing TGF-beta signaling, reducing inflammation responses, and inhibiting the molecular processes associated with elevation of blood uric acid levels in the body. Thus, ERK1/2 inhibition may be a potential approach for the prevention and treatment of hyperuricemic nephropathy.

  • 推荐引用方式
    GB/T 7714:
    Liu Na,Xu Liuqing,Shi Yingfeng, et al. Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats [J].ONCOTARGET,2017,8(20):33807-33826.
  • APA:
    Liu Na,Xu Liuqing,Shi Yingfeng,Fang Lu,&Zhuang Shougang.(2017).Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats .ONCOTARGET,8(20):33807-33826.
  • MLA:
    Liu Na, et al. "Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats" .ONCOTARGET 8,20(2017):33807-33826.
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:11 下载次数:0
浏览次数:11
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部